Next-Generation Stem Cells Cleared for Human Trial
By David Cyranoski,
Nature
| 09. 10. 2014
A Japanese patient with a debilitating eye disease is about to become the first person to be treated with induced pluripotent stem cells, which have generated enthusiastic expectations and earned their inventor a Nobel Prize. A health-ministry committee has vetted researchers' safety tests and cleared the team to begin the experimental procedure.
[Update 12 September: eye specialist Yasuo Kurimoto has now performed the procedure on the first patient, a 70-year-old woman. See 'Japanese woman is first recipient of next-generation stem cells'.]
Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, has been using induced pluripotent stem (iPS) cells to prepare a treatment for age-related macular degeneration. Unlike embryonic stem cells, iPS cells are produced from adult cells, so they can be genetically tailored to each recipient. They are capable of becoming any cell type in the body, and have the potential to treat a wide range of diseases. The CDB trial will be the first opportunity for the technology to prove its clinical value.
In age-related macular degeneration, extra blood vessels form...
Related Articles
By Philip Ball, Quanta Magazine | 06.18.2026
Since its molecular structure was deduced in the 1950s, DNA has been hailed by many biologists as the secret of life. They’ve read and studied the information stored in the DNA found in the cells of living organisms, known as...
By Jennifer Takhar, Carolyn Wilson-Nash, and Chloe He, BioNews | 06.22.2026
Imagine wanting to have a child and discovering, at every stage, that the system was not designed with you in mind. This is the reality for many LGBTQ+ people in the UK who seek fertility treatment each year.
Our study...
By Arche Noah, GMWatch | 06.17.2026
The European Parliament has voted for a wide-reaching deregulation of New Genomic Techniques (NGTs). There was no majority for amendments stopping patents on conventionally classically bred plants or NGT plants. “Today’s vote is a missed opportunity to protect Europe’s farmers...
By Carl Zimmer, The New York Times | 06.04.2026
Scientists at Columbia University have edited the DNA of early human embryos with unprecedented accuracy, an achievement that could open the way to babies engineered with particular characteristics.
The prospect has fueled controversy for years. On the one hand, the...
